Senior Business Intelligence Engineer

CellCarta adds Tempus to CDx Commercialization Lab Network. Aug 06, 2026, 09:15 ET Tempus joins as a second commercial laboratory partnership to support oncology-focused access within CellCarta's CDx Accelerator Model. MONTREAL, Aug. 6, 2026 /PRNewswire/ - CellCarta, a global CRO laboratory supporting the biopharmaceutical industry, today announced a strategic collaboration with Tempus AI, Inc. (NASDAQ: TEM). Under the agreement, CellCarta will include Tempus in its CDx Commercialization Lab Network as the network's second commercial laboratory partner, strengthening oncology-focused companion diagnostics offerings to biopharma sponsors. Within the CellCarta network, the collaboration gives biopharma sponsors a more direct route from companion diagnostic development and regulatory approval to commercial use in U.S. oncology practice. CellCarta develops and validates the CDx, generates the analytical and clinical evidence package, supports regulatory submissions, and performs centralized immunohistochemistry (IHC) and tissue-based testing. For sponsors within the CellCarta CDx Commercialization Lab Network, Tempus will support provider test ordering through Tempus Hub, routing sample testing to CellCarta and transmitting results back to ordering healthcare providers. Tempus joins Sonic Healthcare USA as the second member of CellCarta's CDx Commercialization Lab Network, expanding the network's specialized oncology capabilities alongside Sonic's broad clinical and anatomic pathology reach across multiple disease areas. The Lab Network is part of CellCarta's CDx Accelerator Model, a flexible and modular framework organized around four stages: Build, Validate, Launch, and Transfer. Sponsors can engage CellCarta at the stage that fits their program - from assay development and validation through clinical deployment and regulatory submission. Following approval, CellCarta activates its Commercialization Lab Network partners, such as Tempus and Sonic, to support commercial launch strategies. "Tempus materially strengthens the oncology dimension of our commercialization model," said Ehab A. El-Gabry, MD, Chief Medical Officer and Head of Companion Diagnostics at CellCarta. "Sponsors can develop and validate a companion diagnostic at CellCarta, pursue a single-site approval strategy through our flexible and modular CDx Accelerator Model, and then use an established oncology diagnostics platform to support physician access and ordering. This connects regulatory execution with the realities of commercial launch." "Biopharma sponsors should not have to choose between the speed and control of a centralized CDx strategy and a credible path to physicians and patients," said Christopher Ung, Chief Scientific Business Officer of CellCarta. "Adding Tempus to our network creates a powerful route into U.S. oncology practice. It gives sponsors a practical commercialization channel from a company that oncologists already know and use, while CellCarta maintains continuity from development and regulatory approval through testing." CellCarta launched its CDx Commercialization Lab Network to address a common gap in companion diagnostic programs: securing regulatory approval does not by itself create the commercial infrastructure required for physicians to order a test and for patients to access it. The network connects CellCarta's development, regulatory, and testing capabilities with commercial laboratory partners that have established provider relationships and ordering channels. CellCarta intends to continue expanding the network by geography, therapeutic area, and commercial capability. The company's objective is to give sponsors multiple pathways for launching centralized companion diagnostics while retaining flexibility for later expansion through additional laboratories or an IVD kitted solution. To learn more about CellCarta's companion diagnostic capabilities, visit https://cellcarta.com/cdx-services/ About CellCarta CellCarta is a global CRO laboratory supporting the biopharmaceutical industry. With CAP accreditations and CLIA certifications for specific testing methods and facilities in Canada, USA, Belgium, Australia, and China, CellCarta provides biomarker testing services and customized solutions to pharmaceutical and biotechnology companies. By integrating analytical platforms in immunology, histopathology, proteomics, and genomics, along with sample management and logistics services, CellCarta supports the drug development cycle from discovery to late-stage clinical trials. Visit cellcarta.com and connect with us on LinkedIn and X. Media Contacts Stéphanie Bussières-Marmen, PhD Director, Global Marketing [email protected] Melanie Williams Senior Marketing Communications Specialist, Supreme Optimization [email protected] SOURCE CellCarta

Tempus AI has published a study in Nature Medicine showing its PRISM2 multimodal foundation model can perform diagnostic-grade cancer detection and predict biomarker status and patient prognosis. Developed with Microsoft researchers, PRISM2 outperformed or matched existing slide-level foundation models across diagnostic, biomarker, and patient outcome prediction tasks. The model was trained on 2.3 million whole-slide images and 14 million diagnostic question-answer pairs from nearly 700,000 pathology reports, making it the largest multimodal slide-level pathology dataset to date. PRISM2 combines vision models built from pathology images with large language models, turning routine hematoxylin and eosin slides into biological insights. The model can handle complex diagnostic and prognostic research tasks without specialised fine-tuning. Tempus has made the full PRISM2 model weights publicly available through Hugging Face for research and non-commercial use.

Tempus AI posts first GAAP profit on $97M mark-to-market gain amid slowing growth. SaasRise - Aug 2, 2026 Tempus AI recorded its first GAAP-positive quarter with $5.6 million net income, a result of a $97.4 million mark-to-market gain on marketable securities. Underlying operating loss expanded to $75.9 million as revenue growth decelerated to 22% YoY, and the company faces margin pressure despite a new FDA-cleared tumor-only assay. Why it matters. Tempus AI's first GAAP-positive quarter underscores how accounting adjustments can temporarily mask underlying operational challenges in high-growth SaaS-adjacent health-tech firms. For investors and operators, the case highlights the importance of scrutinizing adjusted earnings versus cash-flow realities, especially when a sizable portion of profit stems from non-recurring fair-value gains. The FDA approval of the tumor-only assay also illustrates how regulatory milestones can create short-term pricing levers, but the lasting competitive advantage will depend on the company's ability to lock in favorable commercial contracts that sustain higher ASPs. The broader SaaS market watches Tempus as a bellwether for AI-driven, data-intensive health platforms that blend software with lab services. The firm's struggle to maintain margin expansion while scaling a capital-intensive diagnostics operation raises questions about the scalability of hybrid models that rely on both software licensing and consumable-driven revenue streams. Success in negotiating ADLT pricing could set a precedent for other lab-centric SaaS players seeking to monetize data assets beyond the traditional fee-for-service model. Key points. * Tempus AI posted GAAP net income of $5.6 million in Q2 2026, driven by a $97.4 million mark-to-market gain. * Operating loss widened to $75.9 million; revenue grew 22% YoY to $382.5 million. * Oncology test volume rose 31% while diagnostics revenue grew 20%, widening the volume-to-revenue gap. * FDA cleared the tumor-only xT CDx assay, granting temporary ADLT pricing power for three quarters. * Adjusted EBITDA of $8.0 million relies on $55.6 million in stock-based compensation add-backs. Analysis. Tempus AI's Q2 results serve as a cautionary tale for hybrid SaaS-lab operators that rely on both data licensing and consumable revenue. The $97 million fair-value gain is a one-off boost that does not alter the underlying economics: a growing cost base, especially stock-based compensation, and a margin squeeze as the company leans more heavily on service delivery. The firm's strategic focus on the Hub platform - the longitudinal data linkage that cannot be bought - is its true moat, but monetizing that asset requires deep integration into payer contracts and provider workflows. The ADLT pricing window offers a narrow window to lock in higher reimbursement rates; failure to do so could reset pricing to market levels, eroding the ASP advantage the FDA approval initially promised. From a market perspective, Tempus illustrates the tension between rapid top-line growth and sustainable profitability in AI-native health SaaS. Competitors that have kept their operations purely software-centric, such as Flatiron Health before its acquisition, have enjoyed higher gross margins and more predictable cash conversion. Tempus's 62.6% diagnostics gross margin is respectable for a lab but lags behind pure-software peers that routinely exceed 80% margins. The company's next inflection point will be whether it can transition the Hub's data insights into recurring subscription revenue that offsets the capital intensity of its lab services. Investors should monitor the upcoming ADLT contract negotiations and the company's ability to meet its 2026 revenue guidance without further dilutive financing. A successful conversion of the temporary pricing advantage into a durable margin uplift could validate the hybrid model and spur a wave of similar AI-driven diagnostic platforms. Conversely, continued cash burn and reliance on non-recurring gains would likely pressure the valuation multiples that have buoyed Tempus's market cap since its IPO.